Trial Profile
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Target Total Therapy for Adult Ph-like Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Tucidinostat (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Idarubicin; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Primary endpoint (Event free survival) has been met.
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Status changed from recruiting to completed.